Suven Life Sciences 

Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative conditions across key markets including India, the United States, Europe, and other international territories. The company's core activities revolve around the discovery and subsequent development of new chemical entities (NCEs) specifically targeting disorders of the central nervous system (CNS). Among its promising pipeline assets are SUVN-502, intended for Alzheimer's disease and associated neuropsychiatric manifestations; SUVN-G3031, a potent and selective inverse agonist of the histamine H3 receptor, aimed at sleep and cognitive impairments; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist designed to alleviate depressive disorders. Further advancing its portfolio, Suven is also working on SUVN-D4010, a potent, selective, orally bioavailable, and brain-penetrant partial agonist of the 5-HT4 receptor for cognitive dysfunctions; SUVN-I6107, addressing cognitive issues and schizophrenia; SUVN-M8036 for various psychiatric ailments; and SUVN-D1044, targeting gastrointestinal conditions. Established in 1989, the company is based in Hyderabad, India. It adopted its current name, Suven Life Sciences Limited, in 2003, having previously operated as Suven Pharmaceuticals Pvt. Ltd. Jasti Property and Equity Holdings Private Limited holds a controlling interest in Suven Life Sciences Limited, making it a subsidiary.